OncLive News Network®

Lori Wirth, MD, discusses the latest NCCN guideline updates in differentiated thyroid cancer. This program focuses on evolving strategies for managing patients with progressive, radioactive iodine–refractory disease, with particular emphasis on the growing role of next-generation sequencing (NGS) and precision oncology. Dr. Wirth highlights how identifying actionable molecular alterations such as kinase fusions have transformed first-line treatment decisions, enabling more targeted and effective therapies that are reshaping the standard of care.

Supported in part by Eisai, content independently produced by OncLive.

We will be discussing the current management approach for patients with differentiated thyroid cancer, with a focus on the role of surgery within the broader treatment landscape.

Supported in part by Eisai, content independently produced by OncLive.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, explore the evolving role of antibody-drug conjugates in the treatment of breast cancer.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, highlight evolving treatment approaches for HER2-mutated non–small cell lung cancer.

Heather Wakelee, MD, and Helena Yu, MD, discuss sequencing strategies in EGFR-mutant NSCLC, including frontline choices, resistance, and emerging targeted therapies.

Jonathan Riess, MD, MS, and Nicolas Villanueva, MD, discuss evolving frontline and sequencing strategies in EGFR-mutant non–small cell lung cancer.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss evolving treatment considerations in EGFR-mutated non–small cell lung cancer.

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss sequencing considerations in relapsed/refractory follicular lymphoma.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss evolving frontline treatments and sequencing considerations in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss optimal approaches to the current management of EGFR-mutated non–small cell lung cancer.

Luis Raez, MD, FACP, FCCP, and Alexander I Spira MD, PhD, FACP, FASCO, share evolving treatment considerations in EGFR-mutated NSCLC.

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss management and adherence strategies in EGFR-mutated non–small cell lung cancer.

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the exploration of combination treatment approaches in myelofibrosis.

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss frontline treatment considerations in EGFR-mutated advanced non–small cell lung cancer.

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, highlight ongoing research in unresectable, nonmetastatic HCC.

Narjust Florez, MD, highlights evolving treatment strategies and considerations for EGFR-mutated advanced non–small cell lung cancer

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, detail management strategies in EGFR-mutated NSCLC.

Hope S. Rugo, MD, and Seth Wander, MD, PhD, examine how real-world evidence is increasingly informing treatment decisions in advanced ER-positive breast cancer.

Kathryn S. Nevel, MD and Michael Veronesi, MD, PhD provide an overview of the evolving imaging strategies in glioma and discuss the use of magnetic resonance imagining and amino acid PET imaging throughout the glioma patient journey.

Amer Zeidan, MBBS, reviews key updates in myelodysplastic syndromes (MDS) presented at the 2025 ASH Annual Meeting. The program highlights real-world and clinical trial data shaping care for patients with lower-risk MDS, including insights on treatment initiation and outcomes with luspatercept

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, explore research behind triplet therapies in acute myeloid leukemia.

Francine Foss, MD, and Matthew Lunning, DO, FACP, provide an in-depth review of the current and evolving treatment landscape for peripheral T-cell lymphoma (PTCL), drawing on data presented at the 2025 ASH Annual Meeting.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss ongoing research with CAR T-cell therapy in multiple myeloma and key data to emerge with this class of agents from the 2025 ASH Annual Meeting.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss continued research and progress with CAR T-cell therapy in multiple myeloma, with updates from ASH 2025.

Lindsay Rein, MD, and Frederick Lansigan, MD, break down key data in non-advanced systemic mastocytosis from the 2025 ASH Annual Meeting.

Michael Wang, MD, and Nakhle Saba, MD, provide a comprehensive overview of the evolving treatment landscape for mantle cell lymphoma, highlighting how frontline strategies and later-line targeted therapies are reshaping clinical practice. They review emerging data on BTK and BCL2 inhibition, novel agents such as sonrotoclax, and combination approaches presented at the 2025 ASH Annual Meeting and Exposition. Wang and Saba also explore ongoing research priorities that may further refine treatment sequencing and improve long-term outcomes for patients with mantle cell lymphoma.

Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), unpack key updates in uveal melanoma, highlighting ongoing research, persisting treatment challenges, and updates from the 2025 ESMO Congress.

OncLive® will be premiering OncLive® News Network: On Location at the 2025 ASH Annual Meeting & Exposition! Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic malignancies during the conference.

This OncLive News Network series examines the expanding role of antibody drug conjugates (ADCs) in the treatment of breast cancer. Experts Paolo Tarantino, MD and Jason Aboudi Mouabbi, MD review key data from ESMO 2025 and describe how ADCs are influencing care across HER2 positive, HER2 low, hormone receptor positive, and triple negative disease. The faculty outline major findings from DESTINY Breast05, DESTINY Breast11, TROPION Breast02, and ASCENT03, emphasizing how trastuzumab deruxtecan, datopotamab deruxtecan, and sacituzumab govitecan are moving into both early and metastatic settings. The discussion highlights clinical considerations such as patient selection, biomarkers, and the influence of brain involvement or early relapse on treatment choice. The experts review safety profiles, supportive care needs, and practical issues related to infusion planning and monitoring. The series concludes with emerging strategies that include combination therapy, next generation targets, and research priorities that will shape future use of ADCs in breast cancer.

Jonathan Webster, MD, and Nikesh Shah, MD, provide a comprehensive overview of the evolving treatment landscape for acute lymphoblastic leukemia (ALL), with a focus on how frontline strategies and immunotherapy integration are reshaping patient outcomes. Across the program, they examine the role of blinatumomab in various clinical contexts, unpack how age and Philadelphia chromosome status influence therapeutic decision-making, and review emerging data for younger adults with BCR::ABL1–negative disease. Webster and Shah also highlight promising research directions and key studies to watch ahead of the 2025 ASH Annual Meeting, underscoring the rapidly advancing science driving future improvements in ALL care.